Silver Spring, Maryland — The U.S. Food and Drug Administration has made a groundbreaking decision by approving the first oral GLP-1 medication specifically for weight loss, produced by Novo Nordisk. This development could significantly enhance access to obesity treatments for many patients, according to healthcare professionals.

Novo Nordisk anticipates the introduction of the oral medication in early 2026. Starting in January, pharmacies and select telehealth providers will offer an initial dosage of 1.5 milligrams for $149 per month. This cost is aligned with pricing available for similar medications through direct-to-consumer platforms established during the previous administration.

While specifics regarding the prices for higher dosages remain undisclosed, Novo Nordisk plans to provide further details on insurance coverage and potential savings for eligible patients closer to the launch date. Following the announcement, shares of Novo Nordisk saw a nearly 10% increase in after-hours trading.

In addition to addressing obesity, the FDA’s approval allows the medication to be prescribed to patients looking to lower their risk of serious cardiovascular events, including heart attack, stroke, or death, particularly in individuals with obesity and existing cardiovascular conditions. This aligns with the approval of the company’s popular weight loss drug, Wegovy, which contains the same active ingredient, semaglutide.

Dave Moore, the executive vice president of U.S. operations at Novo Nordisk, emphasized that introducing an oral option can encourage more patients to engage in discussions with their doctors about weight management. He expressed enthusiasm over the potential impact, highlighting the importance of accessibility and convenience for those seeking treatment.

This innovative pill gives Novo Nordisk a competitive advantage over Eli Lilly, its primary rival in the obesity treatment market, which is preparing to launch its own oral medication. Industry analysts suggest that the race to dominate the oral GLP-1 market could be worth approximately $100 billion by the 2030s.

Market analysts remain optimistic about the prospects of oral medications, forecasting that they could capture around 24% or roughly $22 billion of the global weight loss drug market by the end of the decade. BMO Capital Markets analyst Evan Seigerman noted that this FDA approval could provide a critical boost for Novo Nordisk amid past difficulties in maintaining market share.

The approval was based on the results of a phase three clinical trial involving over 300 adults classified as obese but not diabetic. The trial demonstrated promising results, with participants at a 25-milligram dosage losing an average of 16.6% of their body weight after 64 weeks. This weight loss remained substantial even when considering all patients, including those who discontinued the drug.

Though Novo Nordisk’s pill shows more effectiveness compared to an experimental medication from Eli Lilly still awaiting FDA review, Eli Lilly’s treatment possesses distinct advantages by being easier for the body to absorb without imposing dietary limitations. Patients taking Novo Nordisk’s pill must avoid food or drinks for 30 minutes after taking their daily dosage.

Moore pointed out that the pricing structure of the new oral medication is intended to align more closely with what some patients have been paying for unregulated alternatives that have flooded the market due to shortages and high demand for established GLP-1 treatments. During these shortages, some patients resorted to cheaper compounded versions, although the FDA has since found that the supply of semaglutide has stabilized.

The challenge of illicitly produced alternatives continues to trouble industry leaders, with concerns over the safety of ingredients used in unauthorized compounds. Moore expressed his apprehension about the potential dangers posed by these alternative products, which may not be subjected to the same regulatory scrutiny.

As the healthcare landscape changes with new treatment options becoming available, many individuals seek effective solutions for obesity and related health concerns, marking a significant moment for both patients and pharmaceutical developments.